Craft
Bio-Rad

Bio-Rad

Products

9 K

Q2, 2021

Revenue

$2.9 B

FY, 2021

Market Capitalization

$13.5 B

2023-01-19

Bio-Rad Summary

Company summary

Overview
Bio-Rad Laboratories is a company that develops, manufactures, and sells a range of products and solutions for the life science research and clinical diagnostics markets. It provides life science research, clinical diagnostics, quality controls, process separations, food science, and life science education services such as chromatography protein sample preparation, bacteriology, mycology newborn screening, quality control, food safety testing, etc.
Type
Public
Status
Active
Founded
1952
HQ
Hercules, CA, US | view all locations
Website
https://www.bio-rad.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Norman Schwartz

    Norman Schwartz, Chairman of the Board, President and Chief Executive Officer

    • Andrew Last

      Andrew Last, Executive Vice President, Chief Operating Officer

    • Ilan Daskal

      Ilan Daskal, Executive Vice President, Chief Financial Officer

    • Ajit Ramalingam

      Ajit Ramalingam, Senior Vice President, Chief Accounting Officer

    Operating MetricsView all

    Countries

    36
    2.9%

    Q2, 2021

    Clinical Diagnostic Tests Covered

    300

    FY, 2020

    Products

    9K

    Q2, 2021

    LocationsView all

    49 locations detected

    • Hercules, CA HQ

      United States

      1000 Alfred Nobel Dr

    • Philadelphia, PA

      United States

      1500 John F Kennedy Blvd

    • South Granville, NSW

      Australia

      1a/62 Ferndell St

    • Wien, Wien

      Austria

      Am Europl. 2

    • Temse, Vlaanderen

      Belgium

      3 Winninglaan

    • São Paulo, SP

      Brazil

      Avenida Doutor Chucri Zaidan, 1.240 cj 1902 e 1904 Morumbi Corporate

    and 43 others

    Bio-Rad Financials

    Summary financials

    Revenue (Q3, 2022)
    $680.8M
    Gross profit (Q3, 2022)
    $373.8M
    Net income (Q3, 2022)
    ($164.2M)
    Cash (Q3, 2022)
    $517.9M
    EBIT (Q3, 2022)
    $92.8M
    Enterprise value
    $14.2B

    Footer menu